Magda Carneiro-Sampaio

Magda Carneiro-Sampaio

Auto-generated profile, based on publicly available information

Magda Carneiro-Sampaio

University of São Paulo Medical School São Paulo São Paulo Brazil

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2011 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
PPPatricia Palmeira
Patricia Palmeira
CQCamila Quinello
Camila Quinello
ASAna Lúcia Silveira-Lessa
Ana Lúcia Silveira-Lessa
CZCláudia Augusta Zago
Cláudia Augusta Zago
MCMagda Carneiro-Sampaio
Magda Carneiro-Sampaio
Placental transfer of maternal IgG antibodies to the fetus is an important mechanism that provides protection to the infant while his/her humoral response is inefficient. IgG is the only antibody class that significantly crosses the human placenta. This crossing is mediated by FcRn expressed on syncytiotrophoblast cells. There is evidence that IgG transfer depends on the following: (i) maternal levels of total IgG and specific antibodies, (ii) gestational age, (iii) placental integrity, (iv) IgG subclass, and (v) nature of antigen, being more intense for thymus-dependent ones. These features represent the basis for maternal immunization strategies aimed at protecting newborns against neonatal and infantile infectious diseases. In some situations, such as mothers with primary immunodeficiencies, exogenous IgG acquired by intravenous immunoglobulin therapy crosses the placenta in similar patterns to endogenous immunoglobulins and may also protect the offspring from infections in early life. Inversely, harmful autoantibodies may cross the placenta and cause transitory autoimmune disease in the neonate.

10 July 2021 in Pediatric Drugs
Verified
Journal Article
Closed access
PDF file
VTVitor Cavalcanti Trindade
Vitor Cavalcanti Trindade
MCMagda Carneiro-Sampaio
Magda Carneiro-Sampaio
EBEloisa Bonfa
Eloisa Bonfa
CSClovis Artur Silva
Clovis Artur Silva

15 September 2011 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
FLAVIA AFONSO LIMAFLAVIA AFONSO LIMA
FLAVIA AFONSO LIMA
CMCarlos A Moreira-Filho
Carlos A Moreira-Filho
PRPatricia Locosque Ramos
Patricia Locosque Ramos
HBHelena Brentani
Helena Brentani
LLLeandro de A Lima
Leandro de A Lima
MCMagda Carneiro-Sampaio
Magda Carneiro-Sampaio
The Down syndrome (DS) immune phenotype is characterized by thymus hypotrophy, higher propensity to organ-specific autoimmune disorders, and higher susceptibility to infections, among other features. Considering that AIRE (autoimmune regulator) is located on 21q22.3, we analyzed protein and gene expression in surgically removed thymuses from 14 DS patients with congenital heart defects, who were compared with 42 age-matched controls with heart anomaly as an isolated malformation. Immunohistochemistry revealed 70.48 ± 49.59 AIRE-positive cells/mm2 in DS versus 154.70 ± 61.16 AIRE-positive cells/mm2 in controls (p < 0.0001), and quantitative PCR as well as DNA microarray data confirmed those results. The number of FOXP3-positive cells/mm2 was equivalent in both groups. Thymus transcriptome analysis showed 407 genes significantly hypoexpressed in DS, most of which were related, according to network transcriptional analysis (FunNet), to cell division and to immunity. Immune response-related genes included those involved in 1) Ag processing and presentation (HLA-DQB1, HLA-DRB3, CD1A, CD1B, CD1C, ERAP) and 2) thymic T cell differentiation (IL2RG, RAG2, CD3D, CD3E, PRDX2, CDK6) and selection (SH2D1A, CD74). It is noteworthy that relevant AIRE-partner genes, such as TOP2A, LAMNB1, and NUP93, were found hypoexpressed in DNA microarrays and quantitative real-time PCR analyses. These findings on global thymic hypofunction in DS revealed molecular mechanisms underlying DS immune phenotype and strongly suggest that DS immune abnormalities are present since early development, rather than being a consequence of precocious aging, as widely hypothesized. Thus, DS should be considered as a non-monogenic primary immunodeficiency.

3 August 2011 in Lupus
Verified
Journal Article
Closed access
AJAa Jesus
Aa Jesus
BLBl Liphaus
Bl Liphaus
CSCa Silva
Ca Silva
SBSilvia Yumi Bando
Silvia Yumi Bando
LALec Andrade
Lec Andrade
MCM Carneiro-Sampaio
M Carneiro-Sampaio
Objective: To evaluate the frequency of primary immunodeficiencies (PID) in juvenile systemic lupus erythematosus (JSLE) patients. Methods: Some 72 JSLE patients were analyzed for levels of immunoglobulin classes and IgG subclasses and early components of the classical complement pathway. Determination of C4 gene copy number (GCN) and detection of type I C2 deficiency (D) were also performed. Results: PID was identified in 16 patients (22%): C2D in three, C4D in three, C1qD in two, IgG2D (<20 mg/dl) in four, IgAD (<7 mg/dl) in three, and IgMD ( 0.05). Remarkably, the median of Systemic Lupus International Collaborating Clinics/ACR-damage index (SLICC/ACR-DI) was significantly higher in JSLE patients with PID compared with patients without these abnormalities ( p = 0.0033), likewise the high frequency of SLICC/ACR-DI > 1 ( p = 0.023). Conclusions: A high frequency of PID was observed in JSLE patients, suggesting that these defects may contribute to lupus development. Our findings indicate that these two groups of PID should be investigated in severe pediatric lupus.

17 November 2021 in Clinics
Verified
Journal Article
Open access
TFThais T. Fink
Thais T. Fink
HMHeloisa H.S. Marques
Heloisa H.S. Marques
BGBruno Gualano
Bruno Gualano
LLLivia Lindoso
Livia Lindoso
VBVera Bain
Vera Bain
YZYingying Zheng
Yingying Zheng
To prospectively evaluate demographic, anthropometric and health-related quality of life (HRQoL) in pediatric patients with laboratory-confirmed coronavirus disease 2019 (COVID-19) This was a longitudinal observational study of surviving pediatric post-COVID-19 patients (n=53) and pediatric subjects without laboratory-confirmed COVID-19 included as controls (n=52) was performed. The median duration between COVID-19 diagnosis (n=53) and follow-up was 4.4 months (0.8-10.7). Twenty-three of 53 (43%) patients reported at least one persistent symptom at the longitudinal follow-up visit and 12/53 (23%) had long COVID-19, with at least one symptom lasting for >12 weeks. The most frequently reported symptoms at the longitudinal follow-up visit were headache (19%), severe recurrent headache (9%), tiredness (9%), dyspnea (8%), and concentration difficulty (4%). At the longitudinal follow-up visit, the frequencies of anemia (11% versus 0%, p=0.030), lymphopenia (42% versus 18%, p=0.020), C-reactive protein level of >30 mg/L (35% versus 0%, p=0.0001), and D-dimer level of >1000 ng/mL (43% versus 6%, p=0.0004) significantly reduced compared with baseline values. Chest X-ray abnormalities (11% versus 2%, p=0.178) and cardiac alterations on echocardiogram (33% versus 22%, p=0.462) were similar at both visits. Comparison of characteristic data between patients with COVID-19 at the longitudinal follow-up visit and controls showed similar age (p=0.962), proportion of male sex (p=0.907), ethnicity (p=0.566), family minimum monthly wage (p=0.664), body mass index (p=0.601), and pediatric pre-existing chronic conditions (p=1.000). The Pediatric Quality of Live Inventory 4.0 scores, median physical score (69 [0-100] versus 81 [34-100], p=0.012), and school score (60 [15-100] versus 70 [15-95], p=0.028) were significantly lower in pediatric patients with COVID-19 at the longitudinal follow-up visit than in controls. Pediatric patients with COVID-19 showed a longitudinal impact on HRQoL parameters, particularly in physical/school domains, reinforcing the need for a prospective multidisciplinary approach for these patients. These data highlight the importance of closer monitoring of children and adolescents by the clinical team after COVID-19.

24 April 2015 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MCMagda Carneiro-Sampaio
Magda Carneiro-Sampaio
ACAntonio Coutinho
Antonio Coutinho
Autoimmune disorders (AID) have been increasingly observed in association with monogenic primary immunodeficiencies (PID). Here we discuss the interface between PID and AID, focusing on autoimmune manifestations early in life, which could be diagnostic clues for underlying PIDs. Early-onset inflammatory bowel disease has been associated with IL-10 and IL-10R deficiencies, chronic granulomatous disease, IPEX (Immunedysregulation-Polyendocrinopathy-Enteropathy-X-linked), autoinflammatory disorders and others. Some PIDs have been identified as underlying defects in juvenile systemic lupus erythematosus: C1q-, IgA-, IgM deficiencies, IFN- pathway alterations (in Aicardi–Goutières syndrome due to TREX1 mutation). IPEX, due to FOXP3 mutation leading to Treg cell deficiency, usually appearing in the first months of life, was recently observed in miscarried fetuses with hydrops who presented with CD3+ infiltrating lymphocytes in the pancreas. HLH (hemophagocytic lymphohistiocytosis) due to perforin deficiency was also identified as a cause of fetal hydrops. In conclusion, PID should be suspected in any infant with signs of autoimmunity after excluding transferred maternal effects, or in children with multiple and/or severe AID.